A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus

The purpose of this study is to characterize the pharmacokinetics (PK), pharmacodynamics (PD), and safety of subcutaneous (SC) anifrolumab in pediatric participants with moderate to severe systemic lupus erythematosus (SLE) while on background standard of care (SoC) therapy.

NCT Number	NCT07630714
Lead Sponsor	AstraZeneca
Conditions	Systemic Lupus Erythematosus
Enrollment	24 participants
Start Date	2026-07-28
Primary Completion	2030-09-03 (estimated)
Study Completion	2031-09-05 (estimated)
Updated on ClinicalTrials.gov	2026-06-05